2001
Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease
Henry T, Rocha-Singh K, Isner J, Kereiakes D, Giordano F, Simons M, Losordo D, Hendel R, Bonow R, Eppler S, Zioncheck T, Holmgren E, McCluskey E. Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease. American Heart Journal 2001, 142: 872-880. PMID: 11685177, DOI: 10.1067/mhj.2001.118471.Peer-Reviewed Original ResearchConceptsRecombinant human vascular endothelial growth factorVascular endothelial growth factorMyocardial perfusion imagingEndothelial growth factorHuman vascular endothelial growth factorPerfusion imagingTherapeutic angiogenesisRadionuclide myocardial perfusion imagingGrowth factorMinimal hemodynamic changesSequential intracoronary infusionsCoronary artery bypassStable exertional anginaDose-escalation trialPercutaneous coronary interventionCoronary artery diseaseReversible perfusion defectsSevere myocardial ischemiaFuture clinical trialsStress myocardial perfusion studyExertional anginaMyocardial perfusion studiesSurgical revascularizationArtery bypassEscalation trialSerial Motion Assessment by Reference Tracking (SMART): Application to Detection of Local Functional Impact of Chronic Myocardial Ischemia
Pearlman J, Gertz Z, Wu Y, Simons M, Post M. Serial Motion Assessment by Reference Tracking (SMART): Application to Detection of Local Functional Impact of Chronic Myocardial Ischemia. Journal Of Computer Assisted Tomography 2001, 25: 558-562. PMID: 11473185, DOI: 10.1097/00004728-200107000-00008.Peer-Reviewed Original ResearchTherapeutic coronary angiogenesis: a fronte praecipitium a tergo lupi? *
Simons M. Therapeutic coronary angiogenesis: a fronte praecipitium a tergo lupi? *. AJP Heart And Circulatory Physiology 2001, 280: h1923-h1927. PMID: 11299191, DOI: 10.1152/ajpheart.2001.280.5.h1923.Peer-Reviewed Original ResearchPharmacokinetics and Pharmacodynamics of Recombinant FGF‐2 in a Phase I Trial in Coronary Artery Disease
Bush M, Samara E, Whitehouse MJ, Yoshizawa C, Novicki D, Pike M, Laham R, Simons M, Chronos N. Pharmacokinetics and Pharmacodynamics of Recombinant FGF‐2 in a Phase I Trial in Coronary Artery Disease. The Journal Of Clinical Pharmacology 2001, 41: 378-385. PMID: 11304894, DOI: 10.1177/00912700122010230.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overArea Under CurveCoronary DiseaseEnzyme-Linked Immunosorbent AssayFemaleFibroblast Growth Factor 2Follow-Up StudiesHemodynamicsHeparinHumansInfusions, IntravenousMaleMaximum Tolerated DoseMetabolic Clearance RateMiddle AgedRecombinant ProteinsRegression AnalysisTime FactorsConceptsRecombinant FGF-2Coronary artery diseasePhase I trialFibroblast growth factor-2Artery diseaseI trialSystemic exposureSevere coronary artery diseaseTerminal elimination t1/2Peak plasma concentrationConcentration-time curveMultiple animal modelsDose-response relationshipAcute hemodynamicsGrowth factor 2Chronic ischemiaElimination t1/2Intravenous infusionSingle doseLinear pharmacokineticsDistribution t1/2Plasma concentrationsIntravenous administrationBiphasic eliminationSlow clearanceGENE TRANSFER FOR ANGIOGENESIS IN CORONARY ARTERY DISEASE
Laham R, Simons M, Sellke F. GENE TRANSFER FOR ANGIOGENESIS IN CORONARY ARTERY DISEASE. Annual Review Of Medicine 2001, 52: 485-502. PMID: 11160791, DOI: 10.1146/annurev.med.52.1.485.Peer-Reviewed Original ResearchConceptsPromising novel therapeutic strategyAvailable preclinical dataStandard revascularization strategyPeripheral vascular diseaseCoronary artery diseasePreliminary clinical experienceNovel therapeutic strategiesCell-based vectorsRevascularization strategyArtery diseasePreclinical dataVascular diseaseClinical trialsIschemic heartBlood flowTherapeutic strategiesClinical experienceTherapeutic angiogenesisAngiogenesisDelivery modalitiesGene transfer studiesDiseaseGene transfer vectorsPreliminary naturePatients
2000
Therapeutic Angiogenesis With Recombinant Fibroblast Growth Factor-2 Improves Stress and Rest Myocardial Perfusion Abnormalities in Patients With Severe Symptomatic Chronic Coronary Artery Disease
Udelson J, Dilsizian V, Laham R, Chronos N, Vansant J, Blais M, Galt J, Pike M, Yoshizawa C, Simons M. Therapeutic Angiogenesis With Recombinant Fibroblast Growth Factor-2 Improves Stress and Rest Myocardial Perfusion Abnormalities in Patients With Severe Symptomatic Chronic Coronary Artery Disease. Circulation 2000, 102: 1605-1610. PMID: 11015335, DOI: 10.1161/01.cir.102.14.1605.Peer-Reviewed Original ResearchConceptsAdvanced coronary diseaseCoronary diseaseRFGF-2Day 29Myocardial perfusionDay 180Day 57Chronic coronary artery diseaseTherapeutic angiogenesisRest perfusion scoreStress-induced ischemiaCoronary artery diseaseMyocardial perfusion abnormalitiesSingle photon emissionMechanical revascularizationNonstudy patientsArtery diseaseUncontrolled studiesDose groupPerfusion scanPerfusion abnormalitiesReversibility scoreIntravenous administrationPerfusion scoreFactor 2 (Nrf2) proteinEffect of Intracoronary Recombinant Human Vascular Endothelial Growth Factor on Myocardial Perfusion
Hendel R, Henry T, Rocha-Singh K, Isner J, Kereiakes D, Giordano F, Simons M, Bonow R. Effect of Intracoronary Recombinant Human Vascular Endothelial Growth Factor on Myocardial Perfusion. Circulation 2000, 101: 118-121. PMID: 10637195, DOI: 10.1161/01.cir.101.2.118.Peer-Reviewed Original ResearchMeSH KeywordsCardiotonic AgentsCoronary CirculationCoronary DiseaseCoronary VesselsDipyridamoleDobutamineDose-Response Relationship, DrugDouble-Blind MethodEndothelial Growth FactorsExercise TestHumansInjections, Intra-ArterialLymphokinesRecombinant ProteinsTomography, Emission-Computed, Single-PhotonVascular Endothelial Growth Factor AVascular Endothelial Growth FactorsVasodilator AgentsConceptsRecombinant human vascular endothelial growth factorSingle-photon emission CTVascular endothelial growth factorEndothelial growth factorMyocardial perfusionStress scoresHuman vascular endothelial growth factorGrowth factorPerfusion single-photon emission CTDose-dependent effectPhoton emission CTMyocardial perfusion single photon emission CTCoronary revascularizationRest scorePhase 1 dataAnimal modelsPatientsEmission CTLow dosesTherapeutic angiogenesisVisual findingsPerfusionStatistical significanceClinical applicationScores
1998
Effects of coronary artery disease on expression and microvascular response to VEGF
Métais C, Li J, Li J, Simons M, Sellke F. Effects of coronary artery disease on expression and microvascular response to VEGF. American Journal Of Physiology 1998, 275: h1411-h1418. PMID: 9746492, DOI: 10.1152/ajpheart.1998.275.4.h1411.Peer-Reviewed Original ResearchMeSH KeywordsAdenosine DiphosphateCell DivisionCoronary Artery BypassCoronary DiseaseEndothelial Growth FactorsEndothelium, VascularFemaleGene Expression RegulationGenisteinHeart AtriaHepatocyte Growth FactorHumansIn Vitro TechniquesKineticsLymphokinesMaleMicrocirculationMicroscopy, VideoMiddle AgedMuscle RelaxationMuscle, Smooth, VascularNitric Oxide SynthaseNitric Oxide Synthase Type IINitric Oxide Synthase Type IIINitroarginineProto-Oncogene ProteinsReceptor Protein-Tyrosine KinasesReceptors, Growth FactorReceptors, MitogenReceptors, Vascular Endothelial Growth FactorRNA, MessengerTranscription, GeneticVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-1Vascular Endothelial Growth FactorsVasodilationConceptsCoronary artery diseaseInducible nitric oxide synthaseConstitutive nitric oxide synthaseVascular endothelial growth factorHepatocyte growth factorExpression of VEGFNitric oxide synthaseArtery diseaseNG-nitroMicrovascular responsesOxide synthaseExpression of cNOSL-arginineGrowth factorCoronary microvascular responsesSubstance P responseExogenous vascular endothelial growth factorEndothelial growth factorFlk-1 receptorFlt-1 receptorMild hypercholesterolemiaTyrosine kinase receptorsTyrosine kinase inhibitor genisteinEndothelium dysfunctionVascular responses
1996
Antisense Approach to Restenosis
Simons M. Antisense Approach to Restenosis. Circulation Journal 1996, 60: 1. PMID: 8648878, DOI: 10.1253/jcj.60.1.Peer-Reviewed Original Research
1995
Magnetic resonance mapping demonstrates benefits of VEGF–induced myocardial angiogenesis
Pearlman J, Hibberd M, Chuang M, Harada K, Lopez J, Gladstone S, Friedman M, Sellke F, Simons M. Magnetic resonance mapping demonstrates benefits of VEGF–induced myocardial angiogenesis. Nature Medicine 1995, 1: 1085-1089. PMID: 7489368, DOI: 10.1038/nm1095-1085.Peer-Reviewed Original ResearchConceptsVascular endothelial growth factorMagnetic resonance imagingBlood supplyCoronary occlusive diseasePlacebo-controlled studyCollateral blood supplyBetter ejection fractionCoronary artery occlusionCause of deathCollateral vessel developmentEndothelial growth factorRegional wall thickeningArtery occlusionOcclusive diseaseEjection fractionCollateral vesselsCoronary arteryCollateral developmentIschemic zoneVEGF infusionMyocardial angiogenesisResonance imagingWall thickeningHeart attackPorcine model
1994
The impact of clinical data on interpretation of thallium scintigrams
Simons M, Parker J, Donohoe K, Udelson J, Gervino E. The impact of clinical data on interpretation of thallium scintigrams. Journal Of Nuclear Cardiology 1994, 1: 365-371. PMID: 9420719, DOI: 10.1007/bf02939957.Peer-Reviewed Original ResearchConceptsClinical dataClinical informationCoronary diseaseThallium scansExercise thallium scanThallium lung uptakeCoronary artery diseaseArtery diseaseVentricular dilationLung uptakeThallium scintigramsPerfusion abnormalitiesDiagnostic imaging informationClinical managementScintigraphic dataPatientsCliniciansDiseaseTest scoresScoresScansOverall test scoresImaging informationRadiologistsScintigrams
1993
Relation between Activated Smooth-Muscle Cells in Coronary-Artery Lesions and Restenosis after Atherectomy
Simons M, Leclerc G, Safian R, Isner J, Weir L, Baim D. Relation between Activated Smooth-Muscle Cells in Coronary-Artery Lesions and Restenosis after Atherectomy. New England Journal Of Medicine 1993, 328: 608-613. PMID: 8429852, DOI: 10.1056/nejm199303043280903.Peer-Reviewed Original ResearchConceptsSmooth muscle cellsMyosin heavy chainNonmuscle myosin heavy chainRecurrent luminal narrowingCoronary artery lesionsExercise thallium scintigraphyVascular smooth muscle cellsCoronary atherosclerotic plaquesPresence of restenosisHigh-power fieldGroup of lesionsNegative resultsAngiographic followCoronary atherectomyCoronary angioplastyThallium scintigraphyCoronary lesionsLuminal narrowingNeointimal proliferationSubsequent restenosisLate lossLuminal diameterHeavy chainHigh riskAtherectomy